ReviewMovement disorders : official journal of the Movement Disorder Society2011
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.
Review in Movement disorders : official journal of the Movement Disorder Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease.Molecules (Basel, Switzerland) · 2026Review
- Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson's Disease.Life (Basel, Switzerland) · 2022Article
- Article
- Failure of Diphtheria Toxin Model to Induce Parkinson-Like Behavior in Mice.International journal of molecular sciences · 2021Article
- Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy.Brain : a journal of neurology · 2020Article
- Article
- Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.Scientific reports · 2017Article
- Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease inFrontiers in genetics · 2017Review
- LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?Current neuropharmacology · 2016Review
- Article
- Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.Neurobiology of disease · 2014Article
- LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity.Annals of clinical and translational neurology · 2014Article
- Patient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate models.Stem cells and cloning : advances and applications · 2013Review
- Dangerous duet: LRRK2 and α-synuclein jam at CMA.Nature neuroscience · 2013Article
- Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.Movement disorders : official journal of the Movement Disorder Society · 2013Review
- LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.Molecular neurodegeneration · 2012Article
- Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.ACS chemical neuroscience · 2012Review
- α-synuclein, LRRK2 and their interplay in Parkinson's disease.Future neurology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Dominantly inherited mutations in leucine-rich repeat kinase 2 are the most common cause of familial Parkinson's disease. Understanding leucine-rich repeat kinase 2 biology and pathophysiology is central to the elucidation of Parkinson's disease etiology and development of disease intervention. Recently, a number of genetic mouse models of leucine-rich repeat kinase 2 have been reported utilizing different genetic approaches. Some similarities in Parkinson's disease-related pathology emerge in these genetic models despite lack of substantial neuropathology and clinical syndromes of Parkinson's disease. The systematic characterization of these models has begun to shed light on leucine-rich repeat kinase 2 biology and pathophysiology and is expected to offer the identification and validation of drug targets. In this review, we summarize the progress of genetic leucine-rich repeat kinase 2 mouse models and discuss their utility in understanding much needed knowledge regarding early-stage (presymptomatic) disease progression, identifying drug targets, and exploring the potential to aid compound screening focused on inhibitors of kinase activity of leucine-rich repeat kinase 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.